氧氣驅(qū)動(dòng)硫酸沙丁胺醇吸入溶液與異丙托溴銨溶液治療小兒哮喘臨床觀察

喘臨床觀察王芳;王森20155201671286411.%ObjectiveToinvestigatetheclinicalefficacyOxygenDrivenSalbutamolSulfateInhalationSolutioncombinedwithIpratropiumBromideSolutioninthetreatmentofinfantileasthma.MethodsTotally128childrenpatientswithasthmainourhospitalfromMay2015toJuly2016wererandomlydividedintotwogroups.64caseseachgroup.Thecontrolgroupwastreatedwithconven-tionaltherapy.whilethestudygroupwastreatedwithOxygenDrivenSalbutamolSulfateInhalationSolutioncombinedwithIpratropiumBromideSolution.Theclinicalefficacyofthetwogroupswascompared.theregressiontimeofclinicalsymptoms(cough.shortnessofbreath).pulmonarysymptoms(rales.wheeze).thehospitalizationtime.theincidenceofadversereactions.peakexpiratoryflowratebeforeandaftertreatment.forcedcapacity.forcedexpiratoryvolumeinthefirstsecondoflungfunctionindexswereobserved.ResultsThetotaleffectiverateinthestudygroupissignificantlyhigherthanthatinthecontrolgroup(P<0.05).Theregressiontimeofclinicalsymptoms(cough.shortnessofbreath).pulmonarysymptoms(rales.wheeze).thehospitalizationtimeinthestudygroupissignificantlyshorterthanthoseinthecontrolgroup(P<05).Bothoftheincidencerateofadversereactionsinthetwogroupswerelow(P>0.05).Beforetreatment.thedifferenceofpeakexpiratoryflowrate.forcedvitalcapacity.forcedexpiratoryvolumeinthefirstpulmonaryfunctionindexsinthetwogroupswerenotsignificant(P>0.05).butaftertreatment.thoseindexesweresignificantlyimproved.andthestudygroupwasimprovedmoreobviously(P<0.05).ConclusionTheclinicalefficacyofOxygenDrivenInhalationofSalbutamolSul-fateSolutioncombinedwithIpratropiumBromideSolutioninthetreatmentofinfantileasthmaiseffective.andcanacceleratetheclinicalsymptomssigns.improvelungfunctionwithoutsignificantadversereactions.Itissafeandeffective.andworthyofclinicalpromotion.《中國(guó)藥業(yè)》2017(026)009【總頁數(shù)】3頁(P41-43)【關(guān)鍵詞】氧氣驅(qū)動(dòng)硫酸沙丁胺醇吸入溶液;異丙托溴銨溶液;小兒哮喘;臨床療效【作者】王芳;王森【作者單位】天津市西青醫(yī)院,天津300380;天津市西青醫(yī)院,天津300380【正文語種】中文【中圖分類】R969.4;R974+.3喘鳴音等，不利于患兒的身體健康及生長(zhǎng)發(fā)育，甚至危及其生命安全。硫酸沙丁胺一般資料納入標(biāo)準(zhǔn)：符合哮喘相關(guān)診斷標(biāo)準(zhǔn)同意書。排除標(biāo)準(zhǔn)：藥物禁忌證；肺部結(jié)核；合并先天性心臟病。病例選擇與分組：選擇我院2015年5月至2016年7月小兒哮喘患兒128例，6435291～12(6.71±1.24)36281～12均(6.65±1.21)歲。兩組患兒一般資料比較，差異無統(tǒng)計(jì)學(xué)意義P＞0.05），具有可比性。方法對(duì)照組患者給予常規(guī)治療，包括平喘止咳、強(qiáng)化營(yíng)養(yǎng)支持等。研究組給予氧氣驅(qū)動(dòng)H20113348，規(guī)格為100μg)聯(lián)合異丙托溴銨溶液（山東京衛(wèi)制藥有限公司，國(guó)藥準(zhǔn)字H20120003，規(guī)格為2mL∶5mg）治療。20.9%化吸入，30.25mL，3～70.5mL，70.75mL5～6L/min20min32[6]比較兩組患兒哮喘治療總有效率；觀察并記錄臨床癥狀（如咳嗽、氣急）肺部體征（如肺部羅音、喘鳴音）消失時(shí)間、平均住院觀察時(shí)間；統(tǒng)計(jì)不良反應(yīng)發(fā)生率。顯效：臨床癥狀（如咳嗽、氣急）消退，肺部體征（如肺部羅音、喘鳴音）消失，總有效＝顯效＋有效。統(tǒng)計(jì)學(xué)處理SPSS21.0t檢驗(yàn)。P＜0.05臨床療效研究組哮喘治療總有效率明顯高于對(duì)照組（P＜0.05）1臨床癥狀與體征消失時(shí)間、平均住院觀察時(shí)間研究組患兒的臨床癥狀（如咳嗽、氣急）消退時(shí)間肺部體征（如肺部羅音、喘鳴音）消失時(shí)間，平均住院時(shí)間均短于對(duì)照組患兒（P＜0.05）。詳見表2。肺功能指標(biāo)1（P＞0.05）；組改善幅度更大（P＜0.05）3不良反應(yīng)發(fā)生情況兩組不良反應(yīng)發(fā)生率均較低（P＞0.05），4耐受良好，依從性高[13－16]。本研究結(jié)果顯示，研究組治療總有效率高于對(duì)照組（P＜0.05），研究組臨床癥狀（如咳嗽、氣急）消退時(shí)間、肺部體征（如肺部羅音、喘鳴音）院觀察時(shí)間短于對(duì)照組（P＜0.05），且兩組患兒不良反應(yīng)發(fā)生率均較低（P＞0.05）1（P＜0.05）。呂方方93.3%1顯著，可改善患兒肺功能，縮短臨床癥狀緩解時(shí)間。綜上所述，氧氣驅(qū)動(dòng)硫酸沙丁胺醇吸入溶液與異丙托溴銨溶液治療小兒哮喘的臨床療效確切，可縮短患兒臨床癥狀與體征消退時(shí)間，改善肺功能，安全有效，值得臨床推廣?！鞠嚓P(guān)文獻(xiàn)】2016，6(13):34201322(11):51－53.DexheimerJW，ArnoldDH，AbramoJJ，etal.Developmentofanasthmamanagementsysteminapediatricemergencydepartment[J].InternationalJournalMedicalInformatics，2013，82(4):230－238.422013，22(8):106－107.2012，14(3):61.OkeloSO，EakinMN，PatinoCM，etal.Thepediatricasthmacontrolandcommunicationinstrumentasthmaquestionnaire:Foruseindiversechildrenofages[J].TheJournalofAllergyandClinicalImmunoloy2013132(1):5－62.201357.2012，10(12):311－312.CabanaMD，KunselmanSJ，NyenhuisSM，etal.Researchingasthmaacrossages:InsightsfromtheNationalHearLung，andBloodInst